Teneligliptin add on to monotherapy treatment in patients with type 2 diabetes

Abstract

Background: In patient with type 2 diabetes (T2D) inadequately controlled on monotherapy, teneligliptin is efficacious and safe as add-on to treatment with oral antidiabetic drugs (OADs) or insulin. Data on efficacy of teneligliptin in Indian patients is relatively sparse. Aim of the study was to assess the efficacy of teneligliptin used as add-on treatment in patients inadequately controlled on monotherapy with OADs or insulin.Methods: We retrospectively evaluated the electronic database at our endocrinology clinic from East India. Patients who were treated with teneligliptin (20 mg/day) as add-on to monotherapy with OADs or insulin were identified, and data analysed. Primary assessment parameters were change in glycosylated haemoglobin (HbA1c %), fasting plasma glucose (FPG, mg/dL) and post-prandial plasma glucose (PPG, mg/dL) over 12-week from the addition of teneligliptin. Paired t test and McNemar test applied to derive statistical significance of paired continuous and categorical variables respectively.Results: In 88 patients, teneligliptin was used as add-on treatment in 77.3% and 22.7% patients receiving OAD and insulin as monotherapy respectively. Mean age of population was 48.3±15.1 years and 67% were males. From baseline to 12-weeks, there was significant change in HbA1c (9.6±2.1 to 8.4±1.2%, P<0.001), FPG (181.4±54.5 to 140.9±27.1 mg/dL, P<0.001) and PPG (273.7±75.6 to 201.1±47.7 mg/dL, P<0.001). Reduction in these glycemic parameters was significant in patients with teneligliptin as add-on to either OADs or insulin. Overall, 12.5% patients reached the target HbA1c of <7% after 12-week treatment (P=0.004).Conclusions: In patients who are uncontrolled on monotherapy with either OADs or insulin, addition of teneligliptin resulted in significant reduction of HbA1c, FPG and PPG after 12-week treatment. This establishes usefulness of teneligliptin in Indian patients with T2D. A larger, randomized, comparative study with other gliptins is warranted.

A Single-Center, Observational, Retrospective Cost-Effective Analysis of Treating Inadequately Controlled Type 2 Diabetes Mellitus by Addition of DPP4 Inhibitors Versus Intensified Treatment with Conventional Drugs

“…Between the two groups, HbA1c reduction is significant (P ≤ 0.01). The result was similar to those reported by other studies like Chatterjee, [15] Charbonnel et al, [16] Filozof and Gautier, [19] Muthukrishnan et al, [20] Kesavadev et al, [21] and Sahai et al [18] The current study used CEA, the cost comprised the direct costs involved in buying the drugs only . there was no adverse drug effect reported in any group, so additional cost for management of adverse effect is not included.…”

“…71.4 ± 21.4, compared to the intensification group, 52.7 ± 14.4. The result was similar to those reported by other studies like a study by Sarkar et al, [12] Chatterjee, [15] Gullapalli and Desai, [14] Jeon and Oh, [6] and Sahai et al [18] The primary goal of treatment is to target glycemic control by maintaining the HbA1C level near 6.5% to decrease the incidence of microvascular and macrovascular complications without predisposing study patients to hypoglycemia. It was observed that mean change in the reduction of HbA1c is more in the add on DPP4 group, i.e.…”

“…The result was similar to those reported by other studies like Gullapalli and Desai in a nonrandomized longitudinal intervention study from Karnataka found that the decrement in mean FBS was significantly more in the vildagliptin group than in the glimepiride group which was similar to their study. [14] Another study conducted by Chatterjee, [15] Mitra and Ray, [5] Charbonnel et al, [16] and Devarajan et. al.…”

Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis

“…The effectiveness of teneligliptin in reducing glycemic burden as an add-on to monotherapy has been shown in various studies. A recent study conducted in India demonstrated patients with type 2 DM who had inadequate control of glycemic parameters with monotherapy, teneligliptin (20 mg/day) as add-on to existing treatment significantly reduced HbA1c, FPG, and PPG at 12 weeks, the same duration as that of current study implying again the potential efficacy of addition of teneligliptin on existing monotherapy on uncontrolled glycemic states of type 2 DM patients [22]. In another 16 weeks trial where teneligliptin was added at 20 mg/day to metformin showed a significant reduction in HbA1c (adjusted mean difference -0.90% vs. -0.12%, p<0.0001) and FPG (adjusted mean difference -1.10 mmol/L vs 0.15 mmol/L, p<0.0001) in type 2 DM patients as compared to the placebo group [23].…”